NGS Laboratory Financial Model

Description

This is a comprehensive financial model for a clinical or research Next-Generation Sequencing laboratory, designed to capture the interplay of instrument capacity, reagent lifespan, sample inflow, and technology mix. It goes beyond generic laboratory models by simulating the sequencing run workflow and its direct impact on unit economics.

The model details the acquisition of multiple sequencers of different throughputs, each with its service contract (typically 6–10% of equipment cost per annum), installation, and periodic upgrades. Reagent inventories are modeled per chemistry type, with reorder lead times and shelf-life constraints, reflecting the operational reality where an understock can delay runs while overstock ties up cash.

Revenue is driven by sample volume by test type (whole genome, exome, targeted panel), with pricing flexibility by payer or customer segment. The model calculates per-sample costs dynamically based on multiplexing efficiency, flow cell utilization, and batch size, accurately revealing how margins shift with scale. A dedicated bioinformatics block accounts for cloud compute/storage costs per sample, a frequent oversight in simpler models.

Modeling specifics

• Multi-instrument run scheduling: models parallel sequencing runs on different platforms with distinct cycle times, read lengths, and output capacities, accounting for queue buffering and turnaround time guarantees.
• Reagent inventory management with shelf-life: tracks reagent kits by lot, expiration dates, and consumption per run, triggering reorder points and simulating stock-out risks.
• Dynamic batching and multiplexing: allocates samples to runs based on required read depth, indexing compatibility, and optimal flow cell utilization, directly computing per-sample cost.
• Service contract modeling: separates maintenance into comprehensive vs. parts-only contracts, with annual escalation, reflecting typical 6–12% of equipment cost.
• Bioinformatics cost allocation: computes cloud compute and storage costs per sample type (genome vs. exome) based on data volume, pipeline version, and retention policy.
• Regulatory compliance costs: includes CLIA/CAP certification, proficiency testing fees, and quality control staff time, often omitted in generic lab models.
• Revenue by payer mix: maps tests to diverse payers (commercial, Medicare, self-pay) with distinct payment rates and denial rates, affecting cash collection timing.

What's included in the base version

• Executive dashboard and key KPI summary
• Comprehensive assumptions and scenario manager
• Sequencer capacity and run configuration schedule
• Sample volume forecast by test type and payer
• Reagent inventory and consumption engine with reordering
• Personnel plan including lab, bioinformatics, and administration
• CAPEX schedule (instruments, lab build-out, IT infrastructure)
• Direct sample-level cost allocation model
• Revenue model with payer mix and collection timing
• Financial statements (P&L, Cash Flow, Balance Sheet) on monthly and annual basis
• Financial ratios, breakeven analysis, and sensitivity tables

Common modeling mistakes

• Assuming instruments operate at 100% theoretical capacity without downtime or maintenance — overestimates throughput by 20–30%.
• Modeling reagent costs as a flat percentage of revenue — misrepresents COGS by 10–25% because costs are stepwise per run and batch.
• Neglecting multiplexing efficiency and batch size effects — inflates per-sample gross margin by 15–25 percentage points.
• Ignoring sample re-extraction or re-sequencing due to quality failures — understates direct costs by 5–15%.
• Using a single average price per sample — overestimates net revenue by 10–30% after accounting for payer mix and denials.
• Excluding bioinformatics cloud computation and storage — understates OPEX by $30–$80 per typical genome.